Anti-VEGFR2-labeled enzyme-immobilized metal-organic frameworks for tumor vasculature targeted catalytic therapy.

导出 LinkOut

翻译打印收藏纠错

作者： Jingrong,Zhou ^[1] ; Kai,Wang ^[1] ; Shuaishuai,Ding ^[1] ; Lijuan,Zeng ^[1] ; Jingya,Miao ^[1] ; Yuhua,Cao ^[1] ; Xiao,Zhang ^[2] ; Gan,Tian ^[3] ; Xiu-Wu,Bian ^[4]

作者单位： Institute of Pathology and Southwest Cancer Center, The First Affiliated Hospital, and Key Laboratory of Tumor Immunopathology, Ministry of Education of China, Third Military Medical University (Army Medical University), Chongqing 40038, PR China. ^[1] International Joint Research Center for Precision Biotherapy, and Department of Stem Cell and Regenerative Medicine, The First Affiliated Hospital, Third Military Medical University (Army Medical University), Chongqing 400038, PR China. ^[2] Institute of Pathology and Southwest Cancer Center, The First Affiliated Hospital, and Key Laboratory of Tumor Immunopathology, Ministry of Education of China, Third Military Medical University (Army Medical University), Chongqing 40038, PR China. Electronic address: tiangan09@163.com. ^[3] Institute of Pathology and Southwest Cancer Center, The First Affiliated Hospital, and Key Laboratory of Tumor Immunopathology, Ministry of Education of China, Third Military Medical University (Army Medical University), Chongqing 40038, PR China. Electronic address: bianxiuwu@263.net. ^[4]

关键词 Anti-VEGFR2 Anti-angiogenesis Metal-organic framework Synergistic efficacy Tumor catalytic therapy